Proteasome Inhibitors

Name
Proteasome Inhibitors
Accession Number
DBCAT003056
Description

Compounds that inhibit the function or proteolytic action of the PROTEASOME.

ATC Classification
Drugs
DrugDrug Description
DelanzomibDelanzomib has been used in trials studying the treatment of Solid Tumors, Multiple Myeloma, and Lymphoma, Non-Hodgkin.
BortezomibA proteasome inhibitor used to treat multiple myeloma in patients who have not been successfully treated with at least two previous therapies.
CarfilzomibA proteasome inhibitor used either alone or in conjunction with a chemotherapy regimen to treat patients with relapsed or refractory multiple myeloma.
IxazomibA monoclonal antibody used with other medications to treat multiple myeloma in patients who have received one other therapy already.
Bortezomib D-mannitolNot Annotated
Drugs & Drug Targets
DrugTargetType
BortezomibCytochrome P450 3A4enzyme
BortezomibCytochrome P450 2C19enzyme
BortezomibCytochrome P450 1A2enzyme
BortezomibCytochrome P450 2D6enzyme
BortezomibCytochrome P450 2C9enzyme
BortezomibProteasome subunit beta type-5target
BortezomibProteasome subunit beta type-1target
BortezomibP-glycoprotein 1transporter
BortezomibSolute carrier organic anion transporter family member 1B3transporter
CarfilzomibP-glycoprotein 1transporter
CarfilzomibProteasome subunit beta type-5target
CarfilzomibProteasome subunit beta type-9target
CarfilzomibProteasome subunit beta type-10target
CarfilzomibProteasome subunit beta type-8target
CarfilzomibProteasome subunit beta type-1target
CarfilzomibProteasome subunit beta type-2target
IxazomibCytochrome P450 3A4enzyme
IxazomibCytochrome P450 1A2enzyme
IxazomibCytochrome P450 2B6enzyme
IxazomibCytochrome P450 2C8enzyme
IxazomibCytochrome P450 2D6enzyme
IxazomibCytochrome P450 2C19enzyme
IxazomibCytochrome P450 2C9enzyme